Home › Osteosarcoma › NCT06064682
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion / exclusion criteria - Group1: \- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes Inclusion / exclusion criteria - Group 2: \- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
About the study
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.
What is being tested
- standard of care biopsy (other)
- standard of care biopsy (other)
Sponsor: Jonsson Comprehensive Cancer Center · Participants: 40 · Started: Feb 12, 2024
Contact the study team
- Summer Swearingen · Phone: (424) 766-9349
Official record on ClinicalTrials.gov — NCT06064682
Locations in the U.S.
| California | UCLA / Jonsson Comprehensive Cancer Center, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.